trending Market Intelligence /marketintelligence/en/news-insights/trending/-WDKgJT0X84wtg156fHtTg2 content esgSubNav
In This List

Exelixis seeking US FDA approval to expand drug's use in liver cancer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Exelixis seeking US FDA approval to expand drug's use in liver cancer

Exelixis Inc. completed its submission of a supplemental new drug application to the U.S. Food and Drug Administration for Cabometyx in treating a type of liver cancer.

Cabometyx is already approved as a treatment for renal cell carcinoma, a kidney cancer, and the supplemental new drug application will help expand its indication.

The San Francisco-based biotechnology company made the regulatory submission based on results from the phase 3 Celestial study of Cabometyx, also known as cabozantinib, in patients with previously treated advanced hepatocellular carcinoma.

In March 2017, the FDA granted orphan drug designation to the treatment for the said indication.

Liver cancer is the second-leading cause of cancer deaths globally, with more than 700,000 deaths and nearly 800,000 new cases annually. Hepatocellular carcinoma is the most common form of liver cancer, making up about three-fourths of the roughly 42,000 new cases in the U.S. in 2018.